Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc.

1.48
EUR
-0.04
(-2.51%)
-5.61EPS
30.80MMarket Cap
Mar 11Next Earn

Total Valuation

EUR

As of September 30, 2026, Aligos Therapeutics, Inc. carries a market capitalization of 30.80M, placing it among publicly traded companies globally. Its enterprise value stands at 13.87M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap30.80M
Enterprise Value13.87M

Important Dates

Aligos Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 11, 2027.

Earnings Date3/11/2027

Share Statistics

As of September 30, 2026, Aligos Therapeutics, Inc. has 6.25M shares outstanding.

Shares Outstanding6.25M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 1.73, and the price-to-book ratio stands at 3.09.

PS Ratio1.73
PB Ratio3.09
P/TBV Ratio3.09
P/FCF Ratio-0.85
P/OCF Ratio-0.85

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 0.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 13.87M versus a market cap of 30.80M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.47

Financial Position

As of September 30, 2026, Aligos Therapeutics, Inc. maintains a current ratio of 1.77, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.

Current Ratio1.77
Quick Ratio1.59
Debt / Equity105.25
Debt / EBITDA-0.17

Financial Efficiency

EUR

Over the twelve months ended September 30, 2026, Aligos Therapeutics, Inc. posted a negative return on equity (ROE) of -159.46, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -84.46, reflecting losses generated across the asset base. The company generates approximately 362,022.75 in revenue per employee across its workforce of 82.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-159.46
Return on Assets (ROA)-84.46
Revenue Per Employee362,022.75
Employee Count82.00

Taxes

EUR

Over the twelve months ended September 30, 2026, Aligos Therapeutics, Inc. recorded 3.07M in income tax expense. The company reported a pretax loss of -55.41M and -58.48M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax3.07M

Stock Price Statistics

EUR

As of the close on November 17, 2026, Aligos Therapeutics, Inc.'s stock has declined approximately 74.98% over the past 52 weeks. The 50-day moving average sits at 4.24, while the 200-day moving average is 5.14.

52-Week Price Change-74.98%
50-Day Moving Average4.24
200-Day Moving Average5.14

Income Statement

EUR

Over the twelve months ended September 30, 2026, Aligos Therapeutics, Inc. generated 29.69M in revenue and converted that into -58.48M in net income, yielding earnings per share of -5.61. EBITDA reached -61.33M, while operating income came in at -63.99M.

Revenue29.69M
Operating Income-63.99M
Pretax Income-55.41M
Net Income-58.48M
EBITDA-61.33M
EBIT-63.99M
Earnings Per Share (EPS)-5.61

Balance Sheet

EUR

As of September 30, 2026, Aligos Therapeutics, Inc. holds 27.43M in cash and equivalents against 10.50M in total debt, resulting in a net debt position of -27.43M. Total book value stands at 9.98M, with working capital of 13.31M providing operational flexibility.

Cash & Cash Equivalents27.43M
Total Debt10.50M
Net Debt-27.43M
Equity (Book Value)9.98M
Book Value Per Share1.60
Working Capital13.31M

Cash Flow

EUR

Aligos Therapeutics, Inc. produced -60.32M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -254,984.70 in capital expenditures, free cash flow totaled -60.58M - equivalent to -5.81 per share.

Operating Cash Flow-60.32M
Capital Expenditures-254,984.70
Free Cash Flow-60.58M
FCF Per Share-5.81

Margins

These figures cover the twelve months ended September 30, 2026. The operating margin of -215.55 and net profit margin of -197.01 provide insight into operational efficiency.

Operating Margin-215.55
Pretax Margin-186.65
Profit Margin-197.01
EBITDA Margin-206.59

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -117.93: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.78, meaning Aligos Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-0.78
FCF Yield-117.93

Stock Splits

Aligos Therapeutics, Inc.'s most recent stock split took place on August 19, 2024 with a 25:1 split ratio.

Last Split Date8/19/2024
Split Ratio25:1

Scores

As of September 30, 2026, Aligos Therapeutics, Inc. has an Altman Z-Score of -23.82, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-23.82